Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.78 CAD | 0.00% | +0.27% | +23.93% |
28/02 | Global Healthcare Leader Selects Kneat | CI |
23/02 | Kneat.com Maintained at Buy at Stifel GMP After Q4 Results; Price Target Raised to C$4.15 | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+23.93% | 236M | - | ||
+11.17% | 322B | B- | ||
+24.28% | 216B | B+ | ||
+2.41% | 149B | B | ||
+10.65% | 56.27B | D+ | ||
+8.71% | 32.13B | B+ | ||
-4.57% | 27.45B | C+ | ||
+103.03% | 22.62B | D+ | ||
+22.50% | 19.55B | B- | ||
+13.06% | 14.69B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- KSI Stock
- Ratings kneat.com, inc.